Sign Up for The Swamp Newsletter Must-know stories (and glorious gossip) from the D.C. mire. Email addressSign Up By clicking "Sign Up" you agree to our Terms of Use and Privacy Policy . President Donald Trump appeared to shush a reporter who attempted to ask him a follow

$nwbo @alphavestcap Tremendous uncertainty’ for cancer research as US officials target mRNA vaccines Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stallSat 12 Jul 2025 08.00 EDTMelody SchreiberShareAs US regulators restrict Covid mRNA vaccines and as independent vaccine advisers re-examine the shots, scientists fear that an unlikely target could be next: cancer research.Messenger RNA, or mRNA, vaccines have shown promise in treating and preventing cancers that have often been difficult to address, such as pancreatic cancer, brain tumors and others.But groundbreaking research could stall as federal and state officials target mRNA shots, including ending federal funding for bird flu mRNA vaccines, restricting who may receive existing mRNA vaccines and, in some places, proposing laws against the vaccines.The Trump administration has also implemented unprecedented cuts to cancer research, among other research cuts and widespread layoffs at the National Institutes of Health (NIH). 📷Pregnant doctor denied Covid-19 vaccine sues Trump administrationRead moreAt least 16 grants involving the word “mRNA” have been terminated or frozen, according to the crowdsourced project Grant Watch, and scientists have been told to remove mentions of mRNA vaccines from their research applications, KFF Health News reported in March.Researchers fear that therapeutic cancer vaccines will get “swept up in that tidal wave” against mRNA vaccines, Aaron Sasson, chief of surgical oncology at Stony Brook University, said in April.When it comes to mRNA breakthroughs, “the next couple of years are the most critical”, Elias Sayour, a professor for pediatric oncology research at the University of Florida, said.“If the progress we’ve made to date – which has been prodigious – if that is just stopped or stymied, it can absolutely affect the trajectory and the arc,” he said.The uncertainty around mRNA specifically, and research broadly, could also discourage researchers and institutions from beginning new projects, he said.“If we continue to seize on these gains in the next 10, 20 years, I do see a scenario where we’ve completely transformed how we take care of a large swath of human disease,” he said.Research on mRNA cancer vaccines has been under way for more than a decade, with more than 120 clinical trials on treating and preventing cancers. mRNA shots have shown promise for preventing the return of head and neck cancer; lymphoma; breast cancer, which accounts for 11.6% of all cancer deaths in the US; colorectal cancer; lung cancer; and kidney cancer, among others.Pancreatic cancer has a 10% survival rate and is the second leading cause of cancer deaths in the US, but in a small study, about half of the patients who received an mRNA vaccine did not see their cancer return, and they still had strong immune responses three years later.Early mRNA vaccine trials also indicated the recurrence of melanoma could be cut in half. And a small study co-authored by Sayour on glioblastoma showed the vaccines started affecting the tumors within 48 hours.Like any vaccine, mRNA cancer vaccines train the body to recognize and destroy harmful cells.Unlike foreign pathogens, such as infectious diseases, cancer is caused by the growth of the patient’s own cells.Some cancer vaccines are highly personalized, using a patient’s own cancer cells to treat their tumors or train their immune system to kill off those dangerous cells if they recur.“The ability to create specific vaccines for patients has tremendous, tremendous promise, but that was technology not possible five or 10 years ago,” said Sasson. “It really is a shift in the paradigm of how we treat cancers.”Researchers are also investigating vaccines that would target cancer cells more broadly by identifying “fingerprints” of certain cancers, said Sayour.Additionally, the vaccines could be created for other conditions, such as type 1 diabetes and multiple sclerosis, he said.“It has potential to get rid of a lot of the chronic morbidity we see from disease, to cure diseases that are degenerative, to overcome cancer evolution and cure patients,” Sayour said. “mRNA could be the healthcare that the movable-type printing press was for human knowledge.”Yet federal and state decision-makers have targeted mRNA vaccines in recent months.Vinay Prasad, director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), reportedly overrode scientists at the agency to limit some Covid vaccines, including a new mRNA shot from Moderna, to children older than 12. Prasad also introduced similar limitations on the Covid shot from Novavax, which does not use mRNA.On Thursday, the FDA approved the original Covid mRNA vaccine from Moderna for children between the ages of six months and 11 years – but they narrowed its use to children with at least one underlying condition. (The vaccine for people older than 12 was approved in 2022.)Prasad argued, in two memos recently released by the FDA, that the risks of Covid had dropped, while “known and unknown” side-effects could outweigh the benefits of getting vaccinated.Covid remains a leading cause of death in the US, with 178 deaths in the week ending 7 June, the last week for which the US Centers for Disease Control and Prevention (CDC) offers complete data.At the meeting of the CDC’s advisory committee on immunization practices (ACIP) in June, two of the new vaccine advisers – appointed by the health and human services (HHS) secretary, Robert F Kennedy Jr, after he fired the previous 17 advisers – broached the safety of Covid mRNA vaccines, indicating future scrutiny of these shots.Vicky Pebsworth, a registered nurse who has volunteered for years with the National Vaccine Information Center, said she was “very concerned” about side-effects from the Covid mRNA shots and asked for more data on safety, including “reproductive toxicity”.Shortly before being appointed to the ACIP, Pebsworth and the founder of the National Vaccine Information Center argued that the FDA should not recommend mRNA Covid-19 shots for anyone “until adequate scientific evidence demonstrates safety and effectiveness for both the healthy and those who are elderly or chronically ill”.At the June ACIP meeting, Retsef Levi, a professor of operations management at the MIT Sloan School of Management, said he believed mRNA side-effects were “being reported at rates that are far exceeding other vaccines even when you normalize to the number of doses, which does suggest something, I think”. skip past newsletter promotionSign up to This Week in TrumplandFree newsletterA deep dive into the policies, controversies and oddities surrounding the Trump administrationEnter your email addressSign upPrivacy Notice: Newsletters may contain info about charities, online ads, and content funded by outside parties. For more information see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.after newsletter promotionPreviously, Levi argued: “The evidence is mounting and indisputable that mRNA vaccines cause serious harm including death, especially among young people. We have to stop giving them immediately!”Another new ACIP adviser, Robert Malone, has also repeatedly argued against mRNA vaccines.In 2021, Kennedy, then chair of the anti-vaccine organization Children’s Health Defense, petitioned the FDA to revoke all approvals, and ban future approvals, of all Covid vaccines. He has called Covid shots the “deadliest vaccine ever made”.In May, Kennedy changed Covid vaccine recommendations from “should” to “may” for children, and eliminated the recommendation for pregnant women entirely.Also in May, the US canceled $766m in contracts for research on mRNA vaccines against H5N1 bird flu. Investment in the mRNA vaccine was not “scientifically or ethically justifiable”, Andrew Nixon, the HHS communications director, said in statements to the media, adding that the “mRNA technology remains under-tested”.Millions of mRNA vaccines have been given around the world, and the vaccines have been shown to be safe and effective in multiple studies.Bans or limitations on mRNA vaccinations have been introduced in seven states. One such bill in Idaho sought to pause “gene therapy immunizations” for 10 years – a category in which they incorrectly place Covid vaccines, and which could affect other therapeutics.Similarly, in Washington state, commissioners in Franklin county passed a resolution urging the local health facility to stop providing and promoting gene-therapy vaccines; they also incorrectly included Covid mRNA shots in this category.“There’s this scorched-earth mentality now, but I’m hopeful that once the dust settles, we’ll be able to reinstate or allow vaccine work for cancer purposes to proceed,” Sasson said.Cancer is the second leading cause of death in the US, and two in five people will be diagnosed with some form of cancer in their lifetime.There are currently only two FDA-approved vaccines that prevent cancer – hepatitis B and human papillomavirus (HPV) – and both have been targeted by anti-vaccine activists.In January, Trump hosted the launch of Stargate AI at the White House. The project could eventually identify cancers and develop mRNA vaccines in days, Larry Ellison, the chair of the tech company Oracle who is involved with the project, said at the launch.The project will be funded by private, not federal, dollars, but the work on cancer would draw upon research on cancer and mRNA, among other fields.Yet the Trump administration has slashed other critical funding for cancer research, prevention and treatment.The administration canceled more than $180m in grants through the National Cancer Institute (NCI) in the first three months of its term, and proposed cutting $2.7bn from the cancer center in the next NIH budget.The administration has cut back funding for some family planning providers, which frequently offer screenings for HPV and other cancer markers.Lawmakers have also made enormous cuts to Medicaid and insurance through the Affordable Care Act (ACA), which could mean uninsured and underinsured people wait longer for cancer treatment – or forgo it entirely.“There’s the potential for great harm, for massive public health issues to be set aside during this really broad approach of canceling research,” said Sasson. “There’s significant harm that’s going to happen by these sweeping changes.”For scientists who still have funding or those who are entering the field, “there’s tremendous uncertainty as to what the future will look like”, Sasson said.But he is optimistic that mRNA vaccines for cancer and other illnesses will be able to move forward.Scientists are often portrayed as “just trying to survive” funding cuts, but that’s not entirely accurate, said Sayour, before adding: “I don’t think many people in my field do this because they’re just trying to survive. I would want nothing more, honest to God, than to put myself out of business. We do this because we want to make a difference.”Sayour echoed concerns about both indirect and direct forces shaping progress on mRNA vaccines.“But I also want to be optimistic that our best days are ahead of us,” he sai

@alphavestcap LAST UPDATED ON 27 APR, 2023About the licensing of procurement organisations Procurement is defined as the processes by which tissues and cells are made available, including the physical act of removing tissue and the donor selection and evaluation.Add paragraphIf you or someone within your organisation is carrying out procurement of tissues and / or cells for patient treatment, an HTA licence will normally be required, unless the procurement is being carried out on behalf of a licensed organisation under a third party agreement. In these circumstances:the procuring organisation must be acting on behalf of a licensed establishment; and the third party agreement must meet the standards set out in HTA Directions 001/2021. If you are procuring tissues and / or cells and transferring them to an HTA-licensed tissue establishment for storage and / or processing, please contact the Designated Individual (DI) to ensure that your existing arrangement is valid. In the past, we found that many organisations procuring tissues and / or cells were not acting on behalf of licensed establishments, and needed to apply for a licence.If your organisation requires a procurement licence, you will have to suspend all procurement activity until you have submitted a licence application, the HTA has evaluated it and issued you with a licence for the activity of procurement. This process can take up to three months, depending on factors such as the quality of information provided in the initial application and the degree of compliance with the standards.The HTA does not expect procurement organisations to be fully compliant at the point of application for a licence. Our approach is to work with licence applicants to identify deficiencies and offer advice and guidance about how best to meet them. We will therefore work with licence applicants to agree a timeframe for meeting the requirements of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 Q&S Regulations.FAQs on the licensing of procurement organisations IN THIS SECTION Human Application sector licence forms Removal licence Application forms and guidance Emergency mortuary facilities UK Transition licensing frequently asked questions Licensing exemptions Satellite premises What you need before you apply for a HTA licence Footer Top SIGN UP FOR OUR NEWSLETTER Our newsletter gives an overview of our recent activities and developments in the areas we regulate. It is also an important source of information for professionals working in regulated sectors and transplant approvals.Newsletter email addressSIGN UPSOCIAL MEDIA Footer Big footer Guidance for professionalsCodes of Practice, standards and legislation Licences, roles and fees Inspections Guidance by sector Find an establishment Latest inspection reports Guidance for the publicBody, organ and tissue donation Post mortem examinations Public guides to the HTA Codes of Practice Umbilical cord blood banking About the HTAMeet our Board and Executive Team Committees and working groups Strategy, Business plans and reviews News Blogs FOIs, corporate, operational and incident data Footer Accessibility statement Contact Privacy notice Disclaimer Copyright notice Position on the procurement of tumour material Guidance for establishments on meeting HTA licensing requirements for the procurement of tumour samples to be used as a starting material in the manufacture of an Advanced Therapy Medicinal Product (ATMP).Certain types of immunotherapies require the use of tumour material in their manufacture. Where the tumour material will comprise part of the active substance of the final product, it will be considered to be starting material for the manufacture of an ATMP. The Q&S Regulations will apply for the donation, procurement, testing and import. Detailed standards are set out in the HTA’s Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment, which was brought into effect through the HTA Directions 001/2021Add paragraphThe following scenarios have been developed to set out the HTA licensing requirements for these types of materials. They are intended to act as guidance for those seeking assurance about how to demonstrate that tumour material procured for use in the manufacture of an ATMP meets the UK requirements with respect to donation, procurement, testing and import. Any establishment seeking to conduct this type of activity should contact the HTA for further advice.Scenario one The primary purpose of removing the tumour material is to obtain starting material for ATMP manufacture.A HTA human application licence will be required for procurement and testing where this activity occurs in the UK.If the tumour material is to be imported, then an import licence will be required (see scenario 4 below). If the sample is to be stored, or processed, in the UK prior to transfer to an ATMP manufacturer, then these activities will also need to be licensed by the HTA.Scenario two A tumour biopsy is being obtained for diagnostic purposes, or the patient is undergoing surgery for removal of the tumour. At the time of the procedure, it has been identified that the tumour material could be used for the purposes of ATMP manufacture, and a portion of the material is retained for these purposes.Certain parts of the procurement procedure may not be subject to HTA licensing requirements. This could depend on a number of factors including: the procedure being undertaken to obtain the tumour; and whether the material is transferred directly to an ATMP manufacturer or is held at a tissue bank. In these circumstances, those undertaking the activity should contact the HTA for advice.Regardless of licensing arrangements, all aspects of the procurement must meet the quality and safety standards required by the Q&S Regulations as set out in the HTA’s Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment. As a minimum, consideration must be given to: consent; traceability; SAEARS reporting; and packaging and transport.Donor testing must occur at the time of procurement and this must be performed under the authority of a HTA licence in accordance with the Q&S Regulations requirements.If the sample is to be stored, or processed, prior to moving to an ATMP manufacturer, then these activities will also need to be licensed by the HTA. In these circumstances, once the material has been removed, it should be transferred to an establishment with a HTA human application licence under the supervision of a Designated Individual (DI).Scenario three A tumour biopsy was previously obtained for diagnostic purposes, or the patient underwent surgery for removal of the tumour and the material was retained. At the time of the patient undergoing the procedure, it had not been anticipated that the material would be used as a starting material for ATMP manufacture and the material was not procured, tested or stored in accordance with the Q&S Regulations.The patient is subsequently identified as being suitable for inclusion in a trial for an ATMP and a portion of the retained material will need to be used for the manufacture of this therapy.Where the material has been removed prior to determining it will be used for the development of an ATMP, this could mean that it is not possible to work within the licensing framework of the Q&S Regulations.Once it has been identified that the tumour material will be used for clinical treatment, it should be stored and released in accordance with the Q&S Regulations, under a HTA Human Application licence. Material that has been collected in this way must be subject to a risk assessment identifying areas where procurement and testing has not complied with the requirements of the Q&S Regulations and be subject to a concessional release process, shaped by the outcome of the risk assessment. As part of the concessional release, the ATMP manufacturer must be made aware of any areas of non-conformance. If the sample is to be processed prior to moving to an ATMP manufacturer, then processing will also need to be licensed by the HTA.Scenario four An establishment wishes to import tumour samples into the UK from a third country for use as a potential starting material for the manufacture of an ATMP.The import of starting material from a third country is a HTA licensable activity. The DI will need to ensure that the import of the tumour tissue into the UK meets the requirements of the Q&S Regulations as set out in the Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment, and all other associated documents.The DI of the importing tissue establishment will also need to ensure that imported tumour samples meet the standards of quality and safety equivalent to those required for tissues and cells procured and tested within the UK.If the samples are to be stored, or processed, prior to moving to an ATMP manufacturer, then these activities will also need to be licensed by the HTA.Footer Top SIGN UP FOR OUR NEWSLETTER Our newsletter gives an overview of our recent activities and developments in the areas we regulate. It is also an important source of information for professionals working in regulated sectors and transplant approvals.Newsletter email addressSIGN UPSOCIAL MEDIA Footer Big footer Guidance for professionalsCodes of Practice, standards and legislation Licences, roles and fees Inspections Guidance by sector Find an establishment Latest inspection reports Guidance for the publicBody, organ and tissue donation Post mortem examinations Public guides to the HTA Codes of Practice Umbilical cord blood banking About the HTAMeet our Board and Executive Team Committees and working groups Strategy, Business plans and reviews News Blogs FOIs, corporate, operational and incident data Footer Accessibility statement Contact Privacy notice @HenryMuney#AdventBioservices was licensed for "Procurement". The HTA establishment record was last updated on May 19, 2025. There is also a different designated individual.$NWBO It Is Reasonable and Strongly Supported to Assume: 1. The procurement license is purpose-specific. •HTA does not grant “Procurement” authority lightly—it’s legally and operationally tied to active or imminent therapeutic use. •Advent isn’t a research hospital—it’s a commercial manufacturer. Their procurement license is for product manufacturing, not academic collection. •Thus, the assumption that this license correlates with imminent commercial activity (i.e., approval) is safe and grounded. 2. DCVax-L is the only known product in play. •Advent is wholly contracted to NWBO. They aren’t producing multiple therapies. •This license wasn’t obtained for some speculative future therapy—it’s clearly tied to DCVax-L. •No evidence of other products being developed through Advent has surfaced publicly or in filings. 3. The license was updated now, not months ago. •The timing aligns perfectly with known 10-Q statements about regulatory engagement and readiness. •May 19, 2025 is not random—it appears to be a gating milestone—a final compliance step required before MHRA issues a Marketing Authorisation (MAA). 4. MHRA won’t approve a product if tissue sourcing isn’t compliant. •If Advent lacked Procurement authority, DCVax-L couldn’t be lawfully manufactured for commercial sale. •Therefore, the MHRA likely made this a prerequisite before granting MAA. ⸻ Where Caution Is Warranted: 1. HTA licensing ≠ MAA issuance •This license clears the way, but it’s not the MAA itself. •MHRA approval still requires a final decision, which may follow within days to weeks—but it’s not automatic. 2. Bureaucracies move independently •The HTA and MHRA are separate. Just because HTA granted this license doesn’t guarantee MHRA has acted—yet. •But it does remove the most likely bottleneck to doing so. ⸻ Bottom Line Yes—it is safe, well-supported, and strategically sound to assume: The May 19 procurement license was the final missing piece in the regulatory puzzle, and its granting suggests MHRA approval is now imminent. It’s not a guarantee—but in biotech terms, it’s a very strong signal. If approval doesn’t follow soon, regulators would have to justify why all compliance barriers are cleared, yet the product still isn’t approved—a harder argument to make.

Cette réaction hystérique ne les mènera nulle part, car les Rothschild, leurs trésoriers, ont perdu la guerre financière. C'est pourquoi les journaux britanniques sont aujourd'hui en mesure de faire état d'allégations d'abus sexuels à l'encontre d'Evelyn de Rothschild, l'ancien chef de ce clan. ⤵️ theguardian.com/business/202… La défunte financière Evelyn de Rothschild accusée d'abus durant sa carrière bancaire Exclusif : Plusieurs femmes affirment que le grand patron de la City a exploité sa position pour les harceler ou les agresser sexuellement dans les années 1990 Mardi 4 février 2025 19h05 CETAnna Isaac Partager Sir Evelyn de Rothschild, l'un des financiers les plus célèbres du monde, a été accusé d'avoir profité de sa position au sein de la célèbre banque pour abuser des femmes qui travaillaient avec lui. Les accusations contre De Rothschild, deux ans après sa mort, proviennent de plusieurs femmes qui ont déclaré qu'elles ne se sentaient pas en mesure de faire part de leurs inquiétudes tant qu'il était encore en vie, en raison de sa position au sein de la banque et de l'establishment britannique. Elles ont parlé au Guardian sous couvert d'anonymat. Parmi les allégations, il affirme avoir gravement agressé sexuellement et harcelé plusieurs femmes au milieu et à la fin des années 1990 alors qu'elles travaillaient pour NM Rothschild. De Rothschild avait la réputation d'être un homme autoritaire et craint, une source le décrivant même comme « totalitaire ». Il était conseiller financier de la défunte reine Elizabeth, qu'il accompagnait aux courses de Royal Ascot, et fut anobli en 1989. Bien que historiques, leurs affirmations sont susceptibles de soulever des questions sur la culture de travail vécue par les femmes au sein de l’empire bancaire Rothschild, qui comprend une gamme complexe de services de conseil en patrimoine et de banque d’investissement. De Rothschild, décédé à l'âge de 91 ans, a présidé pendant plus de 20 ans le groupe NM Rothschild et a également siégé au conseil d'administration de l'Economist et de la société mère du Daily Telegraph. Issu d'une des dynasties les plus célèbres du secteur bancaire mondial, il a travaillé pendant 44 ans au sein des entreprises familiales Rothschild. Selon des sources qui ont parlé au Guardian, il aurait utilisé son bureau au sein de NM Rothschild, à deux pas de la Banque d'Angleterre dans la City de Londres, pour forcer les femmes pendant plusieurs années. Plus de huit sources, dont certaines ont une expérience directe des événements, ont décrit des incidents datant du milieu et de la fin des années 1990. Cependant, plusieurs sources ont affirmé que ce type de mauvaise conduite de la part de De Rothschild est resté incontrôlé pendant des décennies. Des sources ont affirmé qu'il « choisissait » les employés subalternes de la banque et les comblait d'attention avant de se comporter de manière inappropriée à leur égard. Leurs récits décrivent des incidents survenus dans les anciens bureaux londoniens du groupe financier, en partie démolis et reconstruits sur St Swithin's Lane, le site occupé pour la première fois par la banque en 1809. Les accusations incluent des agressions sexuelles graves. L'une d'elles comprend une agression violente contre une employée alors qu'elle était une jeune femme qui travaillait pour lui. Une autre allégation est qu'il aurait mis ses mains sous le haut d'une autre femme et sous ses sous-vêtements pour la peloter. Et une troisième femme a affirmé qu'elle avait été forcée d'accomplir un acte sexuel sur lui alors qu'il était assis à son bureau. Ces allégations, qui remontent au milieu et à la fin des années 1990, ont été présentées aux avocats de Rothschild & Co, le groupe qui a succédé à NM Rothschild. Les allégations ont également été présentées à la famille Rothschild par l’intermédiaire des mêmes avocats. Le Guardian a également demandé si quelqu’un au sein de la banque ou de la famille Rothschild était au courant des allégations et, dans l’affirmative, s’ils avaient essayé de s’attaquer au problème. Les avocats de Rothschild & Co ont refusé de répondre s’il existait des informations relatives à la mauvaise conduite de De Rothschild, déclarant seulement qu’un « examen initial de leurs dossiers » n’avait « rien donné », mais ajoutant qu’ils n’avaient pas suffisamment d’informations pour enquêter plus avant. Aucune réponse n’a été reçue au nom de la famille. Le Guardian a également posé des questions sur l'approche actuelle et historique de la banque face aux plaintes pour conduites sexuelles et autres conduites non financières inappropriées. Les accusations portées contre Evelyn de Rothschild sont susceptibles de soulever des questions sur la culture de travail vécue par les femmes au sein de l'empire bancaire Rothschild. Le groupe bancaire a déclaré par l'intermédiaire de ses avocats : « Nous traitons toute plainte rapidement et avec détermination. Nous apprécions la culture que nous avons développée au fil des ans et il n'y a pas de place pour un tel comportement dans notre culture. » Ils ont ajouté : « Si un comportement inapproprié est allégué, y compris une inconduite sexuelle, nous cherchons à établir exactement ce qui s’est passé. Même si une plainte officielle n’est pas toujours déposée, nous enquêtons sur les allégations de comportement qui ne respectent pas nos normes. » Selon certaines sources, De Rothschild aurait encouragé les femmes à penser qu'il pouvait les aider dans leur carrière, en se présentant comme un sponsor ou un défenseur potentiel dans le secteur des services financiers. Il leur demanderait ensuite de se rendre dans son bureau sous prétexte d'une tâche ou d'une conversation liée au travail avant de les harceler ou de les agresser, selon certaines sources. S'ils exprimaient leurs inquiétudes au sujet de ses actions à d'autres membres du personnel, leur emploi serait résilié, souvent avec indemnités, s'ils acceptaient de garder ses activités confidentielles, affirme-t-on. « Il posait des questions pour savoir si vous aviez de bonnes relations. Si ce n'était pas le cas, je pense que vous aviez plus de chances d'être considérée comme une cible légitime », a affirmé une femme. ignorer la promotion de la newsletterInscrivez-vous à Business TodayNewsletter quotidienne gratuitePréparez-vous pour la journée de travail : nous vous indiquerons toutes les actualités et analyses commerciales dont vous avez besoin chaque matinEnter your email addressSign upAvis de confidentialité : les newsletters peuvent contenir des informations sur des organismes de bienfaisance, des publicités en ligne et du contenu financé par des tiers. Pour plus d'informations, consultez notre politique de confidentialité . Nous utilisons Google reCaptcha pour protéger notre site Web et la politique de confidentialité et les conditions d'utilisation de Google s'appliquent.après la promotion de la newsletter Une autre source a affirmé : « C’était son royaume et il jouissait d’une sorte de pouvoir absolu, les gens étaient au courant des paiements et voyaient des employés qui se ressemblaient tous être embauchés. » Selon le registre des entreprises britanniques Companies House, De Rothschild a officiellement démissionné de son poste de directeur de NM Rothschild en mars 2004. Selon les archives Rothschild, qui répertorient l'histoire de la dynastie bancaire, il a renoncé à ses fonctions de président de plusieurs de ses organisations en 2003, après 44 ans dans l'entreprise familiale. En plus de siéger aux conseils d'administration du Telegraph Media Group et de l'Economist, il a également été directeur du trust propriétaire du théâtre Globe. Rothschild est l'une des institutions les plus renommées de la City de Londres et l'une des institutions bancaires européennes les plus historiques, dont les origines remontent au 15e siècle à Francfort, en Allemagne. La famille Rothschild reste étroitement liée à l'institution, en tant qu'actionnaire important. En plus d'être conseiller financier de la reine Elizabeth II, De Rothschild a également fondé une association caritative avec Mark Shand, le frère défunt de la reine actuelle, et a été fréquemment photographié en conversation avec le roi Charles lorsqu'il était prince de Galles. Il partageait avec la famille royale une passion pour les courses de chevaux et était président de United Racehorses, qui possédait les hippodromes de Sandown et d'Epsom. Il s'est marié trois fois. De nombreuses personnalités ont assisté à ses funérailles et son éloge funèbre a été prononcé par Bill Clinton. Le groupe Rothschild, qui regroupe une gamme de services financiers, notamment la banque d'investissement et la gestion de patrimoine, a été au cœur de la vague de privatisations au Royaume-Uni dans les années 1980. Sa filiale londonienne, NM Rothschild & Sons, fut fondée en 1809 par Nathan Mayer Rothschild, proche de la Banque d'Angleterre. L'essor de ses activités de banque d'affaires fut tel qu'en 1826, elle sauva la banque centrale du Royaume-Uni en lui prêtant de l'or. NM Rothschild & Sons a ensuite fusionné avec une autre branche de l' empire bancaire européen de la famille, Paris Orléans SA, et en 2011, la société a changé de nom, passant de NM Rothschild & Sons à Rothschild & Co. En 2015, la société mère du groupe Rothschild, qui s'appelait auparavant Paris Orléans, a également changé de nom pour devenir Rothschild & Co, selon les archives Rothschild. Les accusations contre De Rothschild s'inscrivent dans un contexte de plaintes historiques contre des hommes qui occupaient des postes de pouvoir, notamment l'ancien propriétaire de Harrods, Mohamed Al Fayed. Depuis sa mort il y a deux ans, un certain nombre de femmes se sont manifestées pour porter des accusations contre Fayed, les incidents remontant au milieu des années 1970.

England riots: how has ‘two-tier policing’ myth become widespread? Idea has been propagated by Tommy Robinson and others from far right but claim does not stand up to scrutiny UK politics live – latest updates Tue 6 Aug 2024 11.05 BSTArchie Bland and Vikram Dodd Share Amid escalating far-right violence across England and in Belfast over the past week, instigators and apologists for the rioting have sought to spread a pernicious myth: the idea that white far-right “protesters” are the victims of a “two-tier policing” system that treats them more harshly because of their race and political views. That is an idea propagated by Tommy Robinson, whose real name is Stephen Yaxley-Lennon, as well as Laurence Fox and various other social media demagogues in the past few days. On Monday, Nigel Farage claimed that “ever since the soft policing of the Black Lives Matter protests, the impression of two-tier policing has become widespread”. Yvette Cooper, Keir Starmer, Priti Patel and the Met police chief, Mark Rowley, were all asked about it later in the day. Cooper, Starmer and Patel all rejected the claim; Rowley said nothing, but grabbed the reporter’s microphone. “There are ‘tiers’ in policing response,” said Graham Wettone, who spent 30 years in frontline public order roles with the Met and is the author of a book, How to Be a Police Officer. “Of course there are – because you make operational decisions appropriate to the severity of the situation. But there are not tiers based on preference or favouritism.” What is the origin of the claims? Agitators point to the policing failures that allowed organised grooming gangs of predominantly Asian men to operate in Rochdale in the 2000s. They also claim the Black Lives Matter (BLM) protests in 2020 were treated with kid gloves. The Rochdale abuse was scandalously ignored by police. But the argument that it is a factor in policing today ignores major reforms to the way child sexual exploitation is treated in the region, including the addition of a specialist unit in Greater Manchester police and every Ofsted inspection since 2014 finding that Rochdale now responds to reported cases effectively. The BLM protests were qualitatively different from the events of the past week, as disorder in the centrally organised protests was a relatively marginal feature. Draconian sentences were also handed down after the 2011 riots. “There was actually plenty of criticism of the BLM policing for being heavy-handed,” Wettone said. “The Met used an advance of the mounted branch, one of their most impactful tactics, which I’ve only seen deployed a couple of times in my whole career, and not at any of the incidents in the last week.” How have the claims gained traction? Allegations of a two-tier system had gained currency even before the events of the past week, with claims about the policing of the pro-Palestinian protests in the UK since 7 October. Robert Jenrick, now a Conservative leadership candidate, claimed in March that two-tier policing had governed the police’s handling of those protests. Meanwhile, those on the far right have claimed that the treatment of recent unrest in Harehills, Leeds, after children from a Roma family were taken into care, revealed that the police were unwilling to act when the agitators were from a minority background. And videos have circulated on social media in recent days of what are claimed to be “Asian gangs” attacking white “protesters” with impunity. But these claims do not stand up to scrutiny, either. All of the evidence of those who attended and monitored the Gaza protests suggests that while there were pockets of disorder, the vast majority of those who attended did so peacefully. “There were arrests, and police identifying offences that have led to prosecutions,” Wettone said. “But those who stayed within the law and were respectful were rightly allowed to protest.” skip past newsletter promotionSign up to First EditionFree daily newsletterOur morning email breaks down the key stories of the day, telling you what’s happening and why it mattersEnter your email addressSign upPrivacy Notice: Newsletters may contain info about charities, online ads, and content funded by outside parties. For more information see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.after newsletter promotion The circumstances in Harehills were very different. “It started out looking like a standard call that many officers will go to, an incident at an address with social services trying to remove children,” said Wettone. “And then it blew up with officers coming under attack. And because of how quickly it escalated, withdrawal is the best tactic.” Some of the videos of “Asian gangs” do appear to be real recordings from the past few days – and there was a troubling confrontation between the far right and a group of Asian men in Bolton. But the scale of these incidents pales in comparison with the far-right activity of the past week, and does not justify headlines framing events of Sunday as equal clashes between the two sides. “Clearly there have been some incidents,” Wettone said. “But it doesn’t seem to be pre-planned in the same way.” How has the violence of the past week been policed? The level of persistent violence puts it in a qualitatively different category to the other policing operations that have been mentioned. So does the fact that the initial protests, which later turned into riots, were not organised in consultation with the police. Chief constable BJ Harrington, the national lead for public order policing, put it like this: “We have not seen this level of violence or planned intent of violence from other large marches. This is not about being frustrated or wanting to give the police the runaround to get publicity, this is about trying to frighten communities, damage property and attack police officers.” A different approach was therefore warranted, Wettone said. “It isn’t about numbers. It’s about the risk and the threat that people pose.”

Farm Estate Signs by greencottagedesigns.com #PerformanceHorses #farmsigns #logosigns #addressSign #VeterinarySign

Outdoor acrylic Signs, Address Sign @waterstonehc #dixiesigns #signage #acrylicsign #addresssign #outdoorsign #businesssign #officesign #metalsign #aluminumsign #vinylsigns

Custom Hanging Address Sign with Arrow by greencottagedesigns.com #PVCsign #HangingSign #addresssign #PhilosFolly #Greece

What a gorgeous DIY address sign made by @its.your.space.to.create featuring our Peak Adjustable Ground Spikes!😍 . . . . . #peakproducts #diy #groundspike #spike #groundspikes #diyproject #diyideas ##diyprojects #diyhome #addresssign #sign #diysign

Cottage Sign Hanging Address Carved PVC Lotus Flower Signage greencottagedesigns.com #Cottage #signs #AddressSign #Lotus #LakeHouseSign #Sunnybank

Historic Property Address Sign by greencottagedesigns.com 3/4" thick Carved PVC Sign with Apple Tree #Apple #Orchard #HistoricLand #Property #AddressSign

Sea-Renity Beach House Vacation Rental Address Sign by greencottagedesigns.com Nautical Starfish Carving included⭐️Renderings provided #NauticalSign #Vrbo #SuperHost #BeachSign #addressSign

Now everyone will notice your house without any miss! Thanks to premium LED House Number from PRIMA. Stunning designs and designed to last. Shop now:-primadecorativehardware.com/ #primadecorativehardware #architecture #PrimaHomeHardware #HomeHardware #ledhousenumber #addresssign

Excited to share this item from my #etsy shop: Ceramic Fir Tree house number tile with starry sky #addresssign #housenumbersign etsy.me/2QuSe5K

38" Quarterboard Sign. - #Beachsign #Coastal #Islandlife #boatlife #Lakelife #Addresssign #carolina #etsy #CapeCod #Crabs #personalized #beach #beachlife #BeachHome

Love this color. Benjamin Moore Stormy Gray - We can mix custom colors to match your home #Beachsign #Coastal #Islandlife #boatlife #Lakelife #Addresssign #carolina #etsy #CapeCod #Shells #personalized #beach #beachlife #BeachHome #custom

Always cool to see my signs mounted on homes - #Beachsign #Coastal #Islandlife #boatlife #Lakelife #Addresssign #carolina #etsy #CapeCod #Shells #Driftwood #personalized #beach #beachlife #BeachHome

Feeling Crabby? Maybe this sign can cheer ya up. #Beachsign #Coastal #Islandlife #boatlife #Lakelife #Addresssign #carolina #etsy #SweetHome #Crabs #personalized #beach #beachlife #BeachHome

Building identification signs give professional look to your business. dixiesigns.ca/buildingsigns #buildingsigns #addresssign #signcompany #dixiesigns #outdoorsigns #signagedesign

New Street address sign installed. #mosaic #woodsigns #addresssign #curbappeal #carpentry